←
BioSpace38,564 posts
BioSpace avatar

BioSpace

@biospace

Your source for biopharma news and jobs

◷ Joined February 2009▧ 7,081 Photos and videos
BioSpace avatar
BioSpace@biospace·4h

Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approval based on a positive subgroup signal. hubs.li/Q04FGKF-0

BioSpace avatar
BioSpace@biospace·5h

Layoffs at the FDA, disruptions to research funding and increased tariffs led the investment banking firm Cassel Salpeter to wonder whether the government is strangling the biotech industry. hubs.li/Q04FFSWb0

BioSpace avatar
BioSpace@biospace·6h

Looking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you. hubs.li/Q04FFQzL0

BioSpace avatar
BioSpace@biospace·7h

Speaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings. hubs.ly/Q04FFPWv0

BioSpace avatar
BioSpace@biospace·7h

Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro. hubs.li/Q04FFmS10

BioSpace avatar
BioSpace@biospace·8h

Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population. hubs.li/Q04FFDn40

BioSpace avatar
BioSpace@biospace·9h

Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” according to one biotech consultant. hubs.li/Q04FFcGn0

BioSpace avatar
BioSpace@biospace·9h

The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting PD-1/VEGF developers on notice; Isomorphic raised a $5B series C, largest in biotech history; ObesityWeek & Clinical Trials on Alzheimer’s Disease conferences underway. hubs.li/Q04FFc4J0

BioSpace avatar
BioSpace@biospace·Nov 17

Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals. hubs.li/Q04FwvVr0